Medical/Pharmaceuticals
Docquity delivers 10% market share growth for Philippine-based pharmaceutical client in just one year
* Docquity's leading network of HCPs and proprietary Awareness to Advocacy (A2A) solution complemented the Client's Sales and Marketing team to increase conversions in a highly competitive pain product market * Client was able to grow prescriptions and revenue, with over 80% cost savings comp...
2023-01-18 10:00
5106
Boehringer Ingelheim Malaysia Honored As Top Employer For The Fifth Consecutive Year
* Boehringer Ingelheim is one of 15 global Top Employers worldwide * Achieved Global Recognition and Top Employer Certification in 29 countries From Top Employers Institute® * Outstanding employer benefits with emphasis on wellbeing, attractive work environment, and rewards and recognition...
2023-01-18 09:00
3497
Boehringer Ingelheim Vietnam Honored As Top Employer For The Fourth Consecutive Year
HO CHI MINH CITY, Vietnam, Jan. 18, 2023 /PRNewswire/ -- Boehringer Ingelheim Vietnam has been honored for the fourth year in succession for its outstanding employee benefits with emphasis on wellbeing, attractive work environment, and rewards and recognition. Globally, Boehringer Ingelheim has ...
2023-01-18 09:00
4430
Mental health focus makes Boehringer Ingelheim stand out as Top Employer 2023 in Asia Pacific for Third Consecutive Year
* Boehringer Ingelheim is one of 15 global Top Employers worldwide * Achieved Global Recognition and Top Employer Certification in 29 countries From Top Employers Institute® * Outstanding employer benefits with emphasis on wellbeing, attractive work environment, and rewards and recognition S...
2023-01-18 09:00
3349
Telix Reports Fourth Quarter 2022 Financial Results
MELBOURNE, Australia, Jan. 18, 2023 /PRNewswire/ -- 18 January 2023. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended31 December 2022 (Q4 2022). All figures are in AUD$ ...
2023-01-18 08:50
4005
Transcenta to Present "Trial in Progress" at ASCO-GI 2023 for TST001 (Osemitamab) Combination with Nivolumab, with or without Chemotherapy in Advanced G/GEJ Cancer
SUZHOU, China, Jan. 18, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces that it will present t...
2023-01-18 08:00
3451
Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subjects in China
Study findings suggest that EVER206 is well-tolerated with no new safety signals, supporting next-phase clinical development inChina SHANGHAI, Jan. 18, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest"), a biopharmaceutical company focused on the development, manufacturing and comm...
2023-01-18 07:30
4796
Abbisko Therapeutics Obtains Approval from The China NMPA to Conduct a Phase II Clinical Study of Pimicotinib (ABSK021） in cGVHD
SHANGHAI, Jan. 18, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that its CSF-1R inhibitor, pimicotinib (ABSK021), has been approved by the National Medical Products Administration ("NMPA") of the People's Republic ofChina for a phase II c...
2023-01-18 07:00
4592
Suvoda 2022 Clinical Trials Surge 20% as it Expands Offerings to Include eConsent and eCOA
Company achieves Top Performer status in ISR IRT Benchmark Survey PHILADELPHIA, Jan. 18, 2023 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, surpassed 1...
2023-01-18 07:00
2886
NOVARAD PROVIDES FREE DIGITAL HEALTH RECORD SHARING TECHNOLOGY TO HOSPITALS IN DEVELOPING COUNTRIES
CryptoChart Lite Medical Image Sharing System Provides Secure Medical Imaging and Digital Records Transfer via Secure QR Code or Web Access Code SALT LAKE CITY, Jan. 17, 2023 /PRNewswire/ -- Novarad announced today its release of CryptoChart Lite, a web-based version of the healthcare company's ...
2023-01-17 22:15
3242
LePure Biotech Closes Series C Financing Co-Led by Novo Holdings, General Atlantic, and Goldman Sachs Asset Management
* LePure Biotech is a leading provider of high-quality and innovative single-use bioprocessing solutions inChina * Proceeds will be used to continue to accelerate product innovation and advance LePure Biotech's go-to-market strategy SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- Shanghai LePure Biot...
2023-01-17 22:00
3848
Health in Transportation, NuraLogix Release New Smartphone Face-Scanning Application Aimed at Uncovering Life-Threatening Health Concerns in Professional Drivers
ST. GEORGE, Utah, Jan. 17, 2023 /PRNewswire/ -- Health in Transportation, a health and wellness solution provider for the transportation industry, has partnered with health technology giant NuraLogix to deliver a revolutionary preventative health tool for drivers called CDL Health Scanner. Acces...
2023-01-17 22:00
2930
LePure Biotech Closes Series C Financing Co-Led by Novo Holdings, General Atlantic, and Goldman Sachs Asset Management
SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- Shanghai LePure Biotech Co., Ltd. ("LePure") announced the completion of its Series C financing from a consortium of world-renowned investors co-led by Novo Holdings, General Atlantic and Goldman Sachs Asset Management, with participation from existing inve...
2023-01-17 20:41
4608
Accuray Announces First Patient Treatments in New Zealand With the CyberKnife® System, the World's Only Robotic Radiation Therapy Delivery Device
Auckland Radiation Oncology Selected the Latest-Generation CyberKnife S7™ System to Deliver Precise Treatments More Quickly, so Patients Can Rapidly Return to the Activities They Enjoy SUNNYVALE, Calif., Jan. 17, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Auckla...
2023-01-17 20:35
2889
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC
* World's first anti-PD-1 mAb for the first-line treatment of SCLC * Making a new record with the median OS of 15.8 months in an international, multi-center, phase 3 clinical trial * Granted orphan drug designations by the FDA and the EC, paving the way for international commercialization SH...
2023-01-17 19:42
4369
Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere
HANGZHOU and SHAOXING, China, Jan. 17, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that its wholly owned subsidiary Ascletis Pharmaceuticals Co., Ltd. has entered into a supply agreement of ritonavir tablets with Hainan Simcere Pharmaceutical Co., Ltd., a su...
2023-01-17 08:29
4100
Agilis RoboticsTM Completes New Round of Live Animal Trials with Miniaturized Robotic Instruments for Endoscopic Surgery
HONG KONG, Jan. 17, 2023 /PRNewswire/ -- Agilis RoboticsTM (Agilis), a leading developer of flexible robotic instruments that support endoscopic surgery through natural orifices of the body (e.g. along the gastrointestinal tract and in the bladder), has recently completed the second round of live...
2023-01-17 08:00
4506
AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention in Mainland China
Affamed to obtain sole commercialization rights upon regulatory approval in Mainland China to Galcanezumab, a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP). Target to address unmet medical needs for millions of Chinese migraine patients. SHANGHAI, Jan. 17, ...
2023-01-17 08:00
6160
ESAOTE S.p.A. gets on board with "The Ocean Race: Genova, the Grand Finale".
GENOA, Italy, Jan. 16, 2023 /PRNewswire/ -- Esaote, a leading company in the biomedical sector – in ultrasound, dedicated magnetic resonance imaging and Information Technology for healthcare– is Supporter of "The Ocean Race: Genova, the Grand Finale". As such, it will be taking part in the Round ...
2023-01-16 20:00
10661
Ascletis Announces Dosing of 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19
--The multiple-dose escalation Phase I clinical trial is expected to enroll 72 healthy subjects, and the enrollment is expected to be completed in the first quarter of 2023 --Ascletis has filed global patent applications for ASC11 and related compounds and their use in viral disease HANGZHOU an...
2023-01-16 08:10
4532
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00
Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21Ampotech and Buskowitz Energy Collaborate to Deliver Integrated Energy Solutions Combining Energy Efficiency, Solar and Battery Storage
[Picked up by 262 media titles]
2026-10-14 09:30
DayOne Upsizes Malaysia Financing to US$7.2 Billion; Total Billings Surpass 1GW and Bookings Reach 2.3GW
[Picked up by 262 media titles]
2026-10-14 18:01Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
14114
LEIFRAS Co., Ltd. Reports First Half of Fiscal Year 2026 Financial Results
2026-10-08 09:50
11995
XPENG G9L Completes First Production Trial in Europe
2026-10-08 07:33
11604
